RecruitingPhase 2NCT04587687

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Studying Follicular lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Joseph Tuscano
Principal Investigator
Joseph M Tuscano, M.D
University of California, Davis
Intervention
Bendamustine Hydrochloride(drug)
Enrollment
23 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2026

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Seagen Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04587687 on ClinicalTrials.gov

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Follicular lymphoma →

← Back to all trials